TrialClinical infectious diseases : an official publication of the Infectious Diseases Society of America2025

Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial.

Jürgen K Rockstroh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.